Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 21, 2025BMC NeurologyOpen Access

Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAdil NawazABArsalan BakhtiyarMKMuhammad Ibrahim Khan

Discussion

Loading...

Member takes

Overview

Meta-analysis shows ocrelizumab reduces relapse rates in multiple sclerosis, suggesting well-managed safety but uncertain long-term effects.

Key Points

  • This research aims to evaluate the efficacy and safety of ocrelizumab in treating relapsing-remitting and primary progressive multiple sclerosis.
  • Systematic review and meta-analysis conducted on existing studies
  • Comparison of ocrelizumab efficacy in relapsing-remitting and primary progressive forms
  • Assessment of relapse rates and safety profiles
  • Ocrelizumab significantly reduces relapse rates in multiple sclerosis
  • Safety profile of ocrelizumab is considered manageable
  • Uncertainties remain regarding its impact on composite endpoints and disability progression

Cite This Study

Nawaz et al. (2025) studied this question.

synapsesocial.com/papers/6924e3f2c0ce034ddc34f077https://doi.org/10.1186/s12883-025-04519-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of Ocrelizumab in comparison to placebo for multiple sclerosis: A systematic review and meta-analysis2025
  2. 2Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers2024 · 13 citations
  3. 310 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005)2024 · 5 citations
  4. 4Systematic review on Ocrevus for treatment of multiple sclerosis2024 · 1 citations
  5. 5Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis2024 · 4 citations